Aligning mRNA Progress with Regulatory Streamlining
Behind the Headlines: 2025 Wish List
Vanessa Almendro, Elliot Berger, Benjamin McCloud, and Turna Ray go behind the headlines to discuss their ‘wish list’ for the progression of trends in the bio/pharmaceutical industry.
Emergent and Hikma Enter Six-Year Partnership to Sell Naloxone Spray in US and Canada
Kloxxado was approved by FDA in 2021 for emergency treatment of opioid overdose, and Emergent also distributes the FDA-approved over-the-counter treatment Narcan.
Scribe, Sanofi Report Milestone for In Vivo Program Collaboration
Although specifics about the milestone were not immediately provided, Scribe is eligible to receive more than $1.2 billion for certain research, development, regulatory, and commercial benchmarks.
ImaginAb Next-Gen Therapeutic Candidates to be Purchased by Telix
The transaction adds a pipeline of early-stage drug candidates against high-value targets to Telix’s portfolio, along with other novel targets currently in the discovery stage.
Solid-Phase Peptide Synthesis Scale-Up Facility Opened by BioDuro in Shanghai
This is the latest facility launch for BioDuro, following a kilogram laboratory and compound management center, both on the same site, in October 2024.
Lonza Partners with Iconovo to Formulate and Develop an Intranasal Biologic
Lonza will develop spray-dried formulations for an intranasally delivered biologic using a reformulated biologic drug candidate for obesity in Iconovo’s pipeline.
PackGene Forms Global Alliance with Non-Profit GC4K and Weill Cornell Medicine for Gene Therapy Treatment for Rare Neurological Disease
Under a global alliance with the Australian non-profit GC4K and Weill Cornell Medicine, PackGene aims to deliver a custom-tailored gene therapy solution for hereditary spastic paraplegia type 56, an exceptionally rare neurological disease.
Bora Biologics to Support DotBio’s Novel Antibody Against Cancer Targets
Bora said it will be involved in stages ranging from chemistry, manufacturing, and controls strategy through to clinical development.
Coave Announces €32 Million in Funding for Next-Gen Genetic Medicines
The co-leaders of the financing were Novo Holdings and Bpifrance, with other investments from Invus, UI Investissement, Seroba Life Sciences, Fund+, Kurma Partners, Omnes Capital, and Turenne Capital.
Final Thoughts and Looking Forward: The Future of Pandemic Preparedness
Sustained investment, technological innovation, and collaboration are essential to future pandemic preparedness.
Vaccine Nationalism and Global Health Interdependence
Strategies to combat vaccine hesitancy and ensure equitable global vaccine distribution are explored amidst declining confidence.
Spark Risk: Improving Pandemic Sentinel Warnings
Advances in surveillance, including AI and wastewater monitoring, are critical to detecting and responding to emerging pathogens.
Capacity and Surge Response Leading Into a State of Readiness
Sustaining pandemic readiness requires investment in workforce, infrastructure, and scalable manufacturing practices.
Empowering Informed Decisions: Tools for Navigating Public Health Challenges
Empowering the public with balanced information and enhancing agency alignment are central to navigating public health crises effectively.
An All-Government Approach: Recognizing the Benefits and Drawbacks
The panel covers the benefits and challenges of a unified government pandemic response, focusing on transparency and trust-building.